Type II photodynamic therapy (PDT) is based on the use of photochemical reactions mediated through an interaction between a tumor-selective photosensitizer, photoexcitation with a specific wavelength of light, and production of reactive singlet oxygen. However, the medical application of this technique has been limited due to inaccurate PDT dosimetric methods. The goal of this study is to examine the relationship between outcome (in terms of tumor growth rate) and calculated reacted singlet oxygen concentration ([ 
INTRODUCTION
Photodynamic therapy (PDT) has received much attention in recent years due to their use to detect and treat proliferate disorders, including cancer. [1] [2] [3] PDT requires administration of a photosensitizing drug (PS) that localizes in tumor tissue and is subsequently excited by exposure to a specific wavelength of light.
1-3 PS transfers energy to ground-state tissue oxygen ( 3 O2) and generates singlet-state oxygen ( 2 O1), which is the main cytotoxic species causing therapeutic effect via reacting with the surrounding biological molecules. 4 Although PDT targets malignant cancer cells, and destroy them in a way that causes significantly less harm to the body than are caused by current treatments like chemotherapy, there are still obstacles preventing the widespread clinical use of PDT. The lack of a PDT dosimetry quantity that correlates with PDT efficacy is prominent among these limitations. [5] [6] [7] Under well-oxygenated conditions, PDT dose, i.e., the light dose absorbed by PS is the most well defined biophysical dosimetry quantity and a good predictor of treatment outcome in explicit PDT dosimetry. The quantity of this method is proportional to the time integral of the product of local PS concentration and light fluence rate. However, theoretical and experimental mice studies have shown that in tumors, which are frequently poorly oxygenated to begin with, high fluence rate PDT modality can create even more severe hypoxia during illumination and result in less effective treatment. 4 To overcome this problem and characterize the PDT treatment outcome, it is suggested to account for 2 O1 production during PDT based on its luminescence signals at 1270 nm. [8] [9] [10] However, the rapid reactions of 2 O1 with biological environment as well as the weak and short lifetime luminescence signals (in the range of 30-180 ns) are major obstacles to use this method for the clinical application, especially in interstitial applications.
A macroscopic model with four PDT parameters of initial oxygen consumption rate (ξ), ratio of photobleaching to reaction between 2 O1 and cellular targets (σ), ratio of triplet state (T) phosphorescence to reaction between T and 3 O2 (β) and oxygen perfusion rate to tissue (g) has been introduced in 2010 to determine the reacted singlet oxygen threshold concentration ([ 
O2
]rx for different excitation conditions, which relates directly to the 3-dimensional distribution of PS, light fluence rate (ϕ), and mean tissue oxygenation distribution. 4 In the macroscopic model, spatial distribution of ϕ in tumor is calculated based on diffusion approximation:
The PDT process can be expressed as a set of coupled differential equations incorporating five PS-specific reaction-rates parameters (ξ, β, σ , δ, g) and 1 O2 threshold dose, [ 
The parameters µa and µ's represent absorption and scattering coefficients, respectively. S describes the light source and the symbol Γs denotes the rates at which ground-state oxygen is supplied to the surrounding tissue. δ is the low concentration correction parameter. The parameters used in this study is listed in Table 1 , which is based on previous tumor necrosis study [12] [13] but is refitted with the values of ξ increased by a factor of ln(10) = 2.303 due to the new knowledge that the extinction coefficient for HPPH is actually expressed in base of 10 instead of e.
Establishment of the small animal tumor models for in-vivo studies
As shown in Fig. 1A , radiation-induced fibrosarcoma (RIF) tumors were propagated on the shoulder of female C3H mice (9-11 weeks old) by the intradermal injection of a suspension of 3×10 5 in vitro-maintained cells. When the tumors volume reached ~20-50 mm 3 (about 7-10 days after cell injection), the mice received 0.25 mg/kg HPPH PS by tail vein injection. Then, PDT has been performed following HPPH drug-light intervals of 24 h.
In-vivo tumor growth study
PDT has been performed by surface illumination of the RIF tumor using an experimental setup as well as a diode laser emitting an 8-Watt maximum power and 665nm beam as shown in Figure 1B . The light was delivered via a 140µm-diameter optical fiber and the laser beam was collimated through a coupling lens on the end of the fiber to a 1cm diameter beam spot over the tumor surface. A range of total fluence including different source strengths of 50, 75 and 150 mW/cm 2 and exposure times of 900, 1333, 1667, 1800 and 2700s (total PDT doses of 100, 135 and 250 J/cm 2 ) have been used to span the different growth rate parameters. Tumor-bearing mice with no PS and excitation were considered as controls. To assess the treatment response, width (a) and length (b) of the treated mice and controls have been 
Explicit 1 O2 dosimetry in subcutaneous tumors
The aim of this section is the practical and accurate calculation of the local 1 O2 concentration in tissue, in-vivo. Explicit measurement of ϕ, tissue optical properties (µa and µ's) as well as the PS and tumor-average hemoglobin oxygen saturation (SO2) concentrations are required to rigorously quantify [ 
O2
]rx in tumor. HPPH-PDT treatments with different concentrations of PSs have been performed previously by another study using interstitial catheters in RIF tumors. 12 For sequential measurements of the PS fluorescence emission spectrum along the catheter axis before and after PDT treatment, a side-cut fiber that serves as both an excitation source connected to a 405 nm diode laser and a photodetector has been used. In order to determine the drug concentration in the tumor, the raw spectrum has been fitted using the singular value decomposition (SVD) algorithm, and has been compared with the results obtained in the same manner from a set of phantoms with known drug concentration. The effects of the light absorption and scattering by tissue on the measured PS fluorescence signals has been taken into account by applying correction factors obtained from the phantom studies. [12] [13] Absorption (diffuse reflectance-based) spectroscopy has also been used to determine tumor SO2 before and after PDT. An isotropic fiber-optic detector measured the fluence-rate profiles at a certain distance (normally 3 mm) from the centurial catheter throughout treatment. The spatially-resolved optical properties have been extracted by fitting these data to a diffusion theory model as explained in section 1.1. A range of ϕ and different modes of light delivery was used to calculate the tissue optical properties, initial tumor PS concentration and spatial distribution of ϕ as shown in Table 1 and Figure 2A . [12] [13] The initial values were taken from the previous in-vivo experimental and theoretical studies. 4, [12] [13] 
Statistical analyses
Each tumor growth study was independently carried out two times. The tumor growth factor of any two group is expressed as mean ± standard error of the measurement. To assess the consistency of the measurements, the tumor volumes in each of the two groups were compared by using Kruskal-Wallis tests; 12-14 volume values (number of the days post treatment) were considered for each group. Wilcoxon tests were also used to evaluate whether the growth rate of the tumors in each two groups of samples, control and treated mice, are significantly different from each other. Analyses were carried out using SPSS 14.0 software. Statistical significance was defined at p < 0.05 level (95% confidence level).
RESULTS AND DISCUSSION
To study treatment responses vs. total PDT dose (fluence × exposure time), the excitation of HPPH PS was performed by illumination (at 665 nm) of the RIF tumor surface as shown in Fig. 1B . The treatment conditions included source strengths of 50, 75 and 150 mW/cm 2 and light delivery at 100, 135 and 250 J/cm 2 . Tumor regrowth assay post PDT treatment was used to quantify the treatment effects of PDT. 7 The amounts of [ 1 O2]rx has also been calculated by using the macroscopic model incorporating the information of the HPPH concentration as well as the ϕ and mean tissue oxygenation distributions. The detailed descriptions of the model and the fitting routine can be found elsewhere. 4, [12] [13] Table 2 presents the calculated mean and sum 1 O2 as well as the tumor growth factor k for each of our test conditions compared to untreated animals (control). The correlations between the tumor growth and reacted [ In all cases p < 0.001 showing a statistically significant difference with 95% confidence level.
CONCLUSION
By simplifying and combining the energy transfer processes in PDT, a set of governing equations are produced, which describes the creation of [ 
O2
]rx derived from the type II PDT energy transfer mechanisms is more accurate and a good metric to show the PDT outcomes.
Although the results have shown a good estimation of the PDT treatment outcomes, our study needs more comprehensive mice studies for different PS concentration, drug-light interval and various excitation light doses.
